MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN Drug Patent Profile

When do Mepivacaine Hydrochloride W/ Levonordefrin patents expire, and when can generic versions of Mepivacaine Hydrochloride W/ Levonordefrin launch?

Mepivacaine Hydrochloride W/ Levonordefrin is a drug marketed by Belmora Llc and is included in one NDA.

The generic ingredient in MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN is levonordefrin; mepivacaine hydrochloride. There are two drug master file entries for this compound. Additional details are available on the levonordefrin; mepivacaine hydrochloride profile page.

Summary for MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	4
DailyMed Link:	MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN at DailyMed

Recent Clinical Trials for MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Suez Canal University	N/A
Cairo University	N/A
University of Sao Paulo	N/A

See all MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN clinical trials

US Patents and Regulatory Information for MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Belmora Llc	MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN	levonordefrin; mepivacaine hydrochloride	INJECTABLE;INJECTION	084850-002	Oct 21, 1983		DISCN	No	No

Mepivacaine Hydrochloride W/ Levonordefrin: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Mepivacaine hydrochloride with levonordefrin is a local anesthetic formulation used primarily in dentistry and minor surgical procedures. Its market trajectory is shaped by factors including generic competition, regulatory approvals, and the demand for dental and surgical services. The financial performance of manufacturers is contingent on production costs, market share, and patent expiry.

What is the Chemical Composition and Mechanism of Action?

Mepivacaine hydrochloride with levonordefrin is a combination drug. Mepivacaine hydrochloride is a local anesthetic belonging to the amide group. It functions by reversibly blocking nerve impulse conduction through the selective inhibition of sodium ion influx into the neuron. This action prevents the depolarization required to generate an action potential, thereby producing local anesthesia.

Levonordefrin is a sympathomimetic amine that acts as a vasoconstrictor. When combined with mepivacaine, it constricts blood vessels at the injection site. This vasoconstriction serves multiple purposes: it slows the systemic absorption of mepivacaine, prolonging its duration of action and reducing the risk of systemic toxicity. It also helps to reduce bleeding during surgical procedures.

The typical formulation contains mepivacaine hydrochloride at a concentration of 2%, with levonordefrin at a concentration of 0.05%. The pH of the solution is also a critical parameter, typically ranging from 3.3 to 5.5.

Who are the Key Manufacturers and Their Market Share?

The market for mepivacaine hydrochloride with levonordefrin is characterized by the presence of both branded and generic manufacturers. Major players include Dentsply Sirona (through its Centrix brand), Septodont, and Pac-Dent. Several generic manufacturers also supply the market, contributing to price competition.

Manufacturer	Primary Product(s)	Estimated Market Presence
Dentsply Sirona	Centrix Mepivacaine HCl 2% with Levo	Significant
Septodont	Scandonest Mepivacaine HCl 2% with Levo	Significant
Pac-Dent	Mepivacaine HCl 2% with Levonordefrin	Moderate
Various Generic Labs	Mepivacaine HCl 2% with Levonordefrin	Fragmented

Market share data is dynamic and influenced by pricing strategies, distribution networks, and product availability. Generic competition generally leads to a diffusion of market share among multiple suppliers.

What is the Patent Landscape for Mepivacaine Hydrochloride W/ Levonordefrin?

The core patents covering the initial formulation of mepivacaine hydrochloride with levonordefrin have long expired. Mepivacaine itself was first synthesized in the late 1950s, and its combination with levonordefrin became established in the pharmaceutical market thereafter.

The primary patent expiry for the foundational combination occurred decades ago. For instance, early patents related to mepivacaine date back to the late 1950s and early 1960s. Patents covering specific manufacturing processes or novel delivery systems may still be in effect for certain products, but the fundamental composition is off-patent. This has allowed for the widespread availability of generic versions.

Current patent activity is more likely to focus on:

• Novel formulations or combinations.
• Specific delivery devices or methods.
• Manufacturing process improvements.
• New therapeutic indications (though this is less common for established anesthetics).

However, for the standard 2% mepivacaine hydrochloride with 0.05% levonordefrin injectable solution, the absence of significant, unexpired composition-of-matter patents is a defining characteristic of its market.

What are the Regulatory Approvals and Their Impact?

Mepivacaine hydrochloride with levonordefrin is approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use as a local anesthetic. Regulatory approvals are critical for market entry and continued sales.

Key aspects of regulatory oversight include:

• Drug Master Files (DMFs): Manufacturers must maintain DMFs detailing manufacturing processes, quality control, and drug substance specifications.
• Abbreviated New Drug Applications (ANDAs): Generic manufacturers rely on ANDAs to demonstrate bioequivalence to the reference listed drug (RLD).
• Good Manufacturing Practices (GMP): Adherence to GMP is mandatory for all manufacturing facilities to ensure product quality and safety.
• Labeling Requirements: Approved labeling must accurately reflect indications, contraindications, warnings, and precautions.

The regulatory pathway for generic versions is well-established. Once the exclusivity period for the RLD expires, companies can file ANDAs. The FDA's approval of an ANDA signifies that the generic drug is therapeutically equivalent to the RLD. This regulatory framework facilitates competition and can lead to significant price reductions after initial market entry of generics.

The ongoing availability of these approvals underpins the stability of the supply chain for this anesthetic. Any regulatory action, such as a recall or manufacturing suspension due to GMP violations, would have an immediate impact on market supply and potentially favor competitors.

What is the Market Size and Growth Projection?

The global market for local anesthetics is substantial, with mepivacaine hydrochloride with levonordefrin occupying a segment within it. Precise market size figures for this specific formulation are often embedded within broader categories such as "dental anesthetics" or "amide local anesthetics."

Estimates suggest the global local anesthetic market is valued in the billions of U.S. dollars and is projected to grow at a compound annual growth rate (CAGR) of approximately 5-7% over the next five to seven years. This growth is driven by:

• Increasing prevalence of dental procedures, including routine check-ups, cosmetic dentistry, and implantology.
• Rising demand for minimally invasive surgical procedures in various medical specialties.
• Growing healthcare expenditure in emerging economies.
• An aging global population requiring more dental and minor surgical interventions.

The segment for mepivacaine hydrochloride with levonordefrin is expected to track this broader market trend, with growth influenced by its established use, cost-effectiveness compared to newer anesthetic agents, and continued demand in dental and outpatient settings. However, the presence of generic competition means that volume growth may not directly translate to proportionate revenue growth for individual manufacturers.

What is the Competitive Landscape and Pricing Dynamics?

The competitive landscape is robust, primarily due to the generic nature of the product. Pricing is highly sensitive to competition, with generic manufacturers typically engaging in price wars to gain market share.

Key competitive factors include:

• Price: This is a primary determinant, especially for dental practices and clinics seeking cost-effective solutions.
• Availability and Supply Chain Reliability: Consistent product availability is crucial for healthcare providers.
• Brand Reputation: While generic, established brands can maintain a degree of preference.
• Formulation and Delivery Options: Although standard, minor variations in syringe types or packaging can differentiate products.

Pricing for mepivacaine hydrochloride with levonordefrin typically ranges from a few U.S. dollars per vial or cartridge in bulk wholesale quantities, depending on the supplier and order volume. Prices have generally stabilized or declined over the years due to generic entry. Manufacturers focus on optimizing production costs to maintain profitability in a competitive pricing environment.

What are the Financial Performance Indicators?

The financial performance of companies manufacturing mepivacaine hydrochloride with levonordefrin is a function of their operational efficiency, market penetration, and strategic partnerships. Due to the commodity nature of the product post-patent expiry, profit margins are generally thinner compared to patented pharmaceuticals.

Key financial indicators to monitor include:

• Revenue Growth: This reflects the volume of sales and any minor price adjustments.
• Gross Margins: Impacted by raw material costs (mepivacaine HCl, levonordefrin, excipients), manufacturing overhead, and competitive pricing. Optimization of the supply chain and production processes is critical to maintaining healthy gross margins.
• Operating Expenses: Including R&D (minimal for generic production), sales and marketing (focused on distribution and customer relationships), and administrative costs.
• Net Profitability: The ultimate measure of financial success.

Companies with integrated manufacturing capabilities or strong distribution networks are better positioned to achieve consistent profitability. Acquisitions of smaller generic manufacturers or expansion into new geographic markets can also drive financial growth. For example, a company might leverage its existing infrastructure to produce mepivacaine HCl w/ levonordefrin alongside other established injectable drugs, spreading fixed costs.

What are the Future Trends and Challenges?

Future Trends:

• Increased Demand in Emerging Markets: As healthcare access and disposable incomes rise in developing nations, the demand for basic dental and surgical procedures, and thus anesthetics like mepivacaine HCl w/ levonordefrin, is expected to grow.
• Advancements in Delivery Systems: While the core formulation is mature, innovations in syringe technology, needle design, or pre-filled systems could offer incremental improvements and differentiate products.
• Focus on Cost-Effectiveness: Healthcare systems globally are under pressure to reduce costs. Mepivacaine HCl w/ levonordefrin, being an established and cost-effective anesthetic, is well-positioned to benefit from this trend.

Challenges:

• Intense Generic Competition: The market is saturated with generic options, leading to constant price erosion and pressure on profit margins.
• Raw Material Price Volatility: Fluctuations in the cost of active pharmaceutical ingredients (APIs) and excipients can impact manufacturing costs and profitability.
• Regulatory Hurdles: Maintaining GMP compliance and navigating evolving regulatory requirements can be costly and time-consuming.
• Development of Newer Anesthetics: While not a direct threat to its widespread use in routine procedures, newer anesthetic agents with different properties (e.g., faster onset, shorter duration, reduced systemic effects) could capture niche markets or become preferred in specific clinical scenarios.

The long-term outlook for mepivacaine hydrochloride with levonordefrin remains stable due to its proven efficacy, safety profile, and cost-effectiveness in its primary applications.

Key Takeaways

• Mepivacaine hydrochloride with levonordefrin is an off-patent local anesthetic, leading to a competitive generic market.
• Key manufacturers include Dentsply Sirona, Septodont, and various generic pharmaceutical companies.
• The market is driven by demand for dental and minor surgical procedures, with growth projected in line with the broader local anesthetic market.
• Pricing is aggressive due to extensive generic competition, necessitating a focus on cost-efficient manufacturing and supply chain management.
• Future growth is anticipated in emerging markets, while challenges include price erosion and raw material volatility.

FAQs

1. What is the primary indication for mepivacaine hydrochloride with levonordefrin? The primary indications are local anesthesia for dental procedures and minor surgical interventions where a vasoconstrictor is beneficial.

2. Are there any remaining patents that protect this specific drug formulation? The core composition-of-matter patents for mepivacaine hydrochloride with levonordefrin have expired, allowing for widespread generic production. Patents may exist for specific manufacturing processes or novel delivery systems.

3. How does levonordefrin contribute to the efficacy of mepivacaine hydrochloride? Levonordefrin is a vasoconstrictor that reduces blood flow at the injection site, prolonging the anesthetic effect of mepivacaine and minimizing bleeding.

4. What are the main factors influencing the price of mepivacaine hydrochloride with levonordefrin? The primary factors are the high degree of generic competition, manufacturing costs, and supply chain dynamics.

5. Is mepivacaine hydrochloride with levonordefrin still widely used in dental practices? Yes, it remains a widely used anesthetic in dentistry due to its established safety profile, efficacy, and cost-effectiveness.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-file/drug-master-files

[2] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs). Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/abbreviated-new-drug-applications-andas

[3] International Society of Cardiovascular Pharmacotherapy. (n.d.). Amide Local Anesthetics. Retrieved from https://www.icpnet.org/resources/documents/clinical-guidelines/cardiovascular-drug-therapy/amide-local-anesthetics.pdf

[4] Grand View Research. (2023). Local Anesthetics Market Size, Share & Trends Analysis Report By Type (Injectable, Topical), By Agent Type (Amide, Ester), By End-Use (Hospitals, Clinics, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2023 - 2030.

[5] MarketsandMarkets. (2023). Local Anesthetics Market - Global Forecast to 2028.